EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs

Euitae Kim, Seoyoung Kim, Sung-Wan Kim, Beom-Woo Nam, Kyoung-Uk Lee, Bong Ju Lee, Seung-Hee Won, Chang Hwa Lee, Sung Won Jung, Soo In Kim, Sung Joon Cho, Young-Chul Chung und 5 weitere

Schizophrenia Research · 2025

DOI: 10.1016/j.schres.2025.04.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Schizophrenia Research, 2025. Verfasst von Euitae Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Brain & Cognitive Sciences, College…. Hauptthemen laut MEDLINE: Aripiprazole, Antipsychotic Agents, Schizophrenia, Psychotic Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical, Otsuka Pharmaceutical Development and Commercialization Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting injectable aripiprazole has substantiated safety and efficacy in treating schizophrenia. However, interindividual variability in clinical response to aripiprazole, possibly linked to its D2 partial agonism and D2 upregulation due to prior antipsychotics, has been reported. This study assessed whether there would be symptomatic aggravations or adverse events in clinically stable patients with schizophrenia when switching from oral antipsychotics to aripiprazole once-monthly (AOM), considering prior antipsychotics: oral aripiprazole (Group I) or other D2 antagonists (Group II). This was a 20-week, prospective, open-label, multicenter trial. Clinically stable patients with schizophrenia were assigned to two groups based on their oral antipsychotic medication and received AOM every 4 weeks. The primary endpoint was a change from baseline in the total Positive and Negative Syndrome Scale (PANSS) score. Treatment-emergent adverse events (TEAEs) were monitored. Altogether, 100 patients in Group I and 101 in Group II completed the study. The mean changes (±SD) from baseline in PANSS total score after switching to AOM were - 9.43 ± 9.79 in Group I (p < 0.0001) and - 4.04 ± 8.72 in Group II (p = 0.0102). Compared to Group I, in Group II, more sleep disturbance (p = 0.0243) and psychotic symptoms (p = 0.0042) TEAE emerged after AOM initiation, with both TEAEs resolving during the study. Psychotic symptoms TEAE was associated with faster tapering of the prior oral antipsychotics (p = 0.0269). Initiating AOM did not aggravate symptoms. Furthermore, AOM ameliorated psychotic symptoms without any significant adverse effect, regardless of their prior oral antipsychotics. However, patients previously treated with D2 antagonists may experience transient psychiatric TEAEs that can be minimized with longer cross-titration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleAntipsychotic AgentsSchizophreniaPsychotic DisordersHumansMaleFemaleAdultMiddle AgedAdministration, OralPsychiatric Status Rating ScalesProspective StudiesDrug SubstitutionTreatment OutcomeYoung AdultDrug Administration Schedule

Stichwörter der Autor:innen

AripiprazoleDopamineSchizophreniaUp-regulation

Substanzen

AripiprazoleAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Brain & Cognitive Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Ko…
  • Department of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea.
  • Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.
  • Department of Psychiatry, Konkuk University School of Medicine, Konkuk University Chungju Hospital, Chungju, Republic of Korea.
  • Department of Psychiatry, The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, Republic of Korea.
  • Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.

Förderung

  • Otsuka Pharmaceutical
  • Otsuka Pharmaceutical Development and Commercialization Inc

Zitieren

APA

Kim, E., Kim, S., Kim, S. W., Nam, B. W., Lee, K. U., Lee, B. J., Won, S. H., Lee, C. H., Jung, S. W., In Kim, S., Cho, S. J., Chung, Y. C., Choi, T. K., Cheon, E. J., Baek, J. H., Correll, C. U., & Kwon, J. S. (2025). Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs. Schizophrenia Research. https://doi.org/10.1016/j.schres.2025.04.033

Vancouver

Kim E, Kim S, Kim SW, Nam BW, Lee KU, Lee BJ, et al. Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs. Schizophrenia Research. 2025. doi:10.1016/j.schres.2025.04.033

BibTeX
@article{Kim2025,
  author = {Kim, Euitae and Kim, Seoyoung and Kim, Sung-Wan and Nam, Beom-Woo and Lee, Kyoung-Uk and Lee, Bong Ju and Won, Seung-Hee and Lee, Chang Hwa and Jung, Sung Won and In Kim, Soo and Cho, Sung Joon and Chung, Young-Chul and Choi, Tai Kiu and Cheon, Eun-Jin and Baek, Ji Hyun and Correll, Christoph U and Kwon, Jun Soo},
  title = {Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs},
  journal = {Schizophrenia Research},
  year = {2025},
  doi = {10.1016/j.schres.2025.04.033}
}
Kostenlos starten →